

# Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus

NCT06585514

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	Beijing GoBroad Hospital
<b>Enrollment</b>	18 participants

## Key Eligibility Criteria

---

### Inclusion (14)

- Male or female, aged 3-65 years.
  - Have a diagnosis of SLE and meet the classification criteria of 2019 European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR).
  - Positive antinuclear antibody (ANA): ANA at a titer of e 1:80 on Hep-2 cells or equivalent positive test (ever) and/or a positive anti-dsDNA serum antibody test (based on ELISA assay, e 30 IU/mL).
  - Refractory SLE and/or refractory lupus nephritis (LN):
  - • 4.1 Refractory SLE 4.1.1 Patients received at least 7.5 mg/kg/day of prednisolone to maintain low disease activity or the SLEDAI 2K score e8.
- ... and 9 more (see full listing online)

### Exclusion (30)

- An individual who meets any of the following criteria will be excluded from participation in this study:
  - Impaired consciousness or intracranial hypertension:
  - Intracranial pressure elevation was above 15 mmHg;
  - Organic encephalopathy syndrome, cerebrovascular accident, encephalitis or central nervous system vasculitis, visual impairment, and other brain lesions requiring intervention.
  - Symptomatic congestive heart failure or severe cardiac arrhythmia:
- ... and 25 more (see full listing online)

## Locations (1 total)

---

Beijing GoBroad Hospital, Beijing, Beijing Municipality, China